

from the Ministry of Health, Labour and Welfare, Japan.

REFERENCES

- Abe M, Okochi E, Kuramoto T, Kaneda A, Takato T, Sugimura T, Ushijima T. 2002. Cloning of the 5' upstream region of the rat p16 gene and its role in silencing. *Jpn. J. Cancer Res.* **93**: 1100–1106.
- Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. 1998. Aging and DNA methylation in colorectal mucosa and cancer. *Cancer Res.* **58**: 5489–5494.
- Anway MD, Cupp AS, Uzumcu M, Skinner MK. 2005. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* **308**: 1466–1469.
- Bachman AN, Phillips JM, Goodman JI. 2006. Phenobarbital induces progressive patterns of GC-rich and gene-specific altered DNA methylation in the liver of tumor-prone B6C3F1 mice. *Toxicol Sci.* **91**: 393–405.
- Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA, Zhang L, Farmer AD, Bell CJ, Kim RW, May GD, Woodward JE, Caillier SJ, McElroy JP, Gomez R, Pando MJ, Clendenen LE, Ganusova EE, Schilkey FD, Ramaraj T, Khan OA, Huntley JJ, Luo S, Kwok PY, Wu TD, Schroth GP, Oksenberg JR, Hauser SL, Kingsmore SF. 2010. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. *Nature* **464**: 1351–1356.
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007. High-resolution profiling of histone methylations in the human genome. *Cell* **129**: 823–837.
- Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? *Nat. Rev. Cancer* **6**: 107–116.
- Biard DS, Maratrat M, Thybaud V, Melcion C, Sarasin A. 1992. Flow cytometric detection of drugs altering the DNA methylation pattern. *Cancer Res.* **52**: 5213–5218.
- Bird A. 2007. Perceptions of epigenetics. *Nature* **447**: 396–398.
- Boffa LC, Mariani MR, Parker MI. 1994. Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate. *Exp. Cell Res.* **211**: 420–423.
- Bromer JG, Wu J, Zhou Y, Taylor HS. 2009. Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. *Endocrinology* **150**: 3376–3382.
- Bromer JG, Zhou Y, Taylor MB, Doherty L, Taylor HS. 2010. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB J*
- Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielonkiewicz P, Suhai S, Wiessler M, Lyko F. 2005. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. *Cancer Res.* **65**: 6305–6311.
- Carnell AN, Goodman JI. 2003. The long (LINEs) and the short (SINEs) of it: altered methylation as a precursor to toxicity. *Toxicol Sci.* **75**: 229–235.
- Cedar H, Bergman Y. 2009. Linking DNA methylation and histone modification: patterns and paradigms. *Nat. Rev. Genet.* **10**: 295–304.
- Cervoni N, Szyf M. 2001. Demethylase activity is directed by histone acetylation. *J. Biol. Chem.* **276**: 40778–40787.
- Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, Fujii H, Nagai H, Fukayama M. 2006. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. *Clin. Cancer Res.* **12**: 2995–3002.
- Chen H, Ke Q, Kluz T, Yan Y, Costa M. 2006. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. *Mol. Cell. Biol.* **26**: 3728–3737.
- Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. 1998. DNA hypomethylation leads to elevated mutation rates. *Nature* **395**: 89–93.
- Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU. 2003. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J. Natl. Cancer Inst.* **95**: 399–409.
- Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nat. Genet.* **24**: 132–138.
- Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. 2002. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. *Cancer Res.* **62**: 6442–6446.
- Curt GA, Kelley JA, Fine RL, Huguenin PN, Roth JS, Batist G, Jenkins J, Collins JM. 1985. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). *Cancer Res.* **45**: 3359–3363.
- Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S, Jacob ST. 2009. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. *Cancer Res.* **69**: 4277–4285.
- de Smet C, Lurquin C, Lethe B, Martelange V, Boon T. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. *Mol. Cell Biol.* **19**: 7327–7335.
- Detich N, Bovenzi V, Szyf M. 2003. Valproate induces replication-independent active DNA demethylation. *J. Biol. Chem.* **278**: 27586–27592.
- Doerfler W, Orend G, Schubert R, Fichteler K, Heller H, Wilgenbus P, Schroer J. 1995. On the insertion of foreign DNA into mammalian genomes: mechanism and consequences. *Gene.* **157**: 241–245.
- Eden A, Gaudet F, Waghmare A, Jaenisch R. 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* **300**: 455.

- Egger G, Liang G, Aparicio A, Jones PA. 2004. Epigenetics in human disease and prospects for epigenetic therapy. *Nature* **429**: 457–463.
- El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. *J. Exp. Med.* **205**: 2409–2417.
- Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC, Bastian PJ, von Ruecker A. 2010. Global levels of histone modifications predict prostate cancer recurrence. *Prostate* **70**: 61–69.
- Fan J, Kodama E, Koh Y, Nakao M, Matsuoka M. 2005. Halogenated thymidine analogues restore the expression of silenced genes without demethylation. *Cancer Res.* **65**: 6927–6933.
- Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. 2003. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res.* **63**: 7563–7570.
- Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. *Nat. Rev. Cancer* **4**: 143–153.
- Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M. 2005a. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc. Natl. Acad. Sci. USA* **102**: 10604–10609.
- Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. 2005b. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. *Nat. Genet.* **37**: 391–400.
- Fujita N, Watanabe S, Ichimura T, Tsuruzoe S, Shinkai Y, Tachibana M, Chiba T, Nakao M. 2003. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. *J. Biol. Chem.* **278**: 24132–24138.
- Fuks F. 2005. DNA methylation and histone modifications: teaming up to silence genes. *Curr. Opin. Genet. Dev.* **15**: 490–495.
- Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. 2002. FK228 (depsipeptide) as a natural pro-drug that inhibits class I histone deacetylases. *Cancer Res.* **62**: 4916–4921.
- Gan Q, Yoshida T, McDonald OG, Owens GK. 2007. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. *Stem. Cells* **25**: 2–9.
- Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, Osada H, Zhang J, Issa JP, Sekido Y. 2008. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. *Carcinogenesis* **29**: 1901–1910.
- Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 2005. 5-aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol. Cell Biol.* **25**: 4727–4741.
- Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. 1997. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. *J. Biol. Chem.* **272**: 22322–22329.
- Hayashi H, Nagae G, Tsutsumi S, Kaneshiro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H. 2007. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. *Hum. Genet.* **120**: 701–711.
- Hellman A, Chess A. 2007. Gene body-specific methylation on the active X chromosome. *Science* **315**: 1141–1143.
- Hermann A, Goyal R, Jeltsch A. 2004a. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA progressively with high preference for hemimethylated target sites. *J. Biol. Chem.* **279**: 48350–48359.
- Hermann A, Gowher H, Jeltsch A. 2004b. Biochemistry and biology of mammalian DNA methyltransferases. *Cell. Mol. Life Sci.* **61**: 2571–2587.
- Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M. 2009. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. *Cancer Res.* **69**: 2766–2774.
- Hogarth LA, Redfern CP, Teodoridis JM, Hall AG, Anderson H, Case MC, Coulthard SA. 2008. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. *Biochem Pharmacol* **76**: 1024–1035.
- Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ. 2005. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. *Clin. Cancer Res.* **11**: 3862–3868.
- Holliday R. 1991. Mutations and epimutations in mammalian cells. *Mutat. Res.* **250**: 351–363.
- Holliday R, Ho T. 2002. DNA methylation and epigenetic inheritance. *Methods* **27**: 179–183.
- Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. 1998. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Res.* **58**: 3942–3945.
- Hublitz P, Albert M, Peters AH. 2009. Mechanisms of transcriptional repression by histone lysine methylation. *Int. J. Dev. Biol.* **53**: 335–354.
- Issa JP, Kantarjian HM. 2009. Targeting DNA methylation. *Clin. Cancer Res.* **15**: 3938–3946.
- Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. 2001. Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res.* **61**: 3573–3577.

- Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. 1994. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat. Genet.* 7: 536–540.
- Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. 2005. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *J. Clin. Oncol.* 23: 3948–3956.
- Jones PA. 1985. Altering gene expression with 5-azacytidine. *Cell* 40: 485–486.
- Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 20: 85–93.
- Jones PA, Baylin SB. 2007. The epigenomics of cancer. *Cell* 128: 683–692.
- Jones PA, Baylin SB, Bernsten BE, Feinberg AP, Grealley JM, Jenuwein T, Jirtle R, Ushijima T, Pierotta V, Allis CD, Elgin SC, Rine J, Wu C. 2008. Moving AHEAD with an international human epigenome project. *Nature* 454: 711–715.
- Kalhan SC. 2009. Metabolism of methionine *in vivo*: impact of pregnancy, protein restriction, and fatty liver disease. *Nestle Nutr. Workshop Ser. Pediatr Program* 63: 121–131; discussion 131–123, 259–168.
- Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi M, Sugimura T, Tatematsu M, Ushijima T. 2004a. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. *Cancer Sci.* 95: 58–64.
- Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, Li E, Sasaki H. 2004b. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. *Nature* 429: 900–903.
- Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY. 2002. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. *Am. J. Pathol.* 160: 787–794.
- Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. *Clin. Cancer Res.* 9: 3578–3588.
- Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, Pikarski E, Young RA, Niveleau A, Cedar H, Simon I. 2006. Evidence for an instructive mechanism of de novo methylation in cancer cells. *Nat. Genet.* 38: 149–153.
- Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc. Natl. Acad. Sci. USA* 100: 11606–11611.
- Klose RJ, Zhang Y. 2007. Regulation of histone methylation by demethylination and demethylation. *Nat. Rev. Mol. Cell Biol.* 8: 307–318.
- Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. 2000. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. *Hepatology* 32: 970–979.
- Kondo Y, Shen L, Cheng AS, Ahmed S, Bumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. 2008. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. *Nat. Genet.* 40: 741–750.
- Kouzarides T. 2007. Chromatin modifications and their function. *Cell* 128: 693–705.
- Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Gottlicher M. 2003. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. *EMBO J.* 22: 3411–3420.
- Laird CD, Pleasant ND, Clark AD, Sneed JL, Hassan KM, Manley NC, Vary JC, Jr., Morgan T, Hansen RS, Stoger R. 2004. Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. *Proc. Natl. Acad. Sci. USA* 101: 204–209.
- Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 81: 197–205.
- Laird PW. 2010. Principles and challenges of genome-wide DNA methylation analysis. *Nat. Rev. Genet.* 11: 191–203.
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham J, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Showkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM,

- Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blocker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglu S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kasprzyk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowski J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, Szustakowski J, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ. 2001. Initial sequencing and analysis of the human genome. *Nature* **409**: 860–921.
- Law JA, Jacobsen SE. 2010. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. *Nat. Rev. Genet* **11**: 204–220.
- Lee BH, Yegnasubramanian S, Lin X, Nelson WG. 2005. Procainamide is a specific inhibitor of DNA methyltransferase 1. *J. Biol. Chem.* **280**: 40749–40756.
- Lee CK, Shibata Y, Rao B, Strahl BD, Lieb JD. 2004. Evidence for nucleosome depletion at active regulatory regions genome-wide. *Nat. Genet.* **36**: 900–905.
- Lee TI, Johnstone SE, Young RA. 2006. Chromatin immunoprecipitation and microarray-based analysis of protein location. *Nat. Protoc.* **1**: 729–748.
- Li B, Carey M, Workman JL. 2007. The role of chromatin during transcription. *Cell.* **128**: 707–719.
- Li E, Bestor TH, Jaenisch R. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell.* **69**: 915–926.
- Li Q, Ke Q, Costa M. 2009. Alterations of histone modifications by cobalt compounds. *Carcinogenesis* **30**: 1243–1251.
- Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, Egger G, Gal-Yam EN, Jones PA. 2007. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. *Cancer Cell.* **12**: 432–444.
- Loeb LA. 2001. A mutator phenotype in cancer. *Cancer Res.* **61**: 3230–3239.
- Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* **389**: 251–260.
- MacGregor JT, Casciano D, Muller L. 2000. Strategies and testing methods for identifying mutagenic risks. *Mutat. Res.* **455**: 3–20.
- Maciejewska Rodrigues H, Jungel A, Gay RE, Gay S. 2009. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. *Mol Immunol*
- MacPhee DG. 1998. Epigenetics and epimutagens: some new perspectives on cancer, germ line effects and endocrine disrupters. *Mutat. Res.* **400**: 369–379.
- Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arai K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. 2006. High levels of aberrant DNA methylation in *Helicobacter pylori*-infected gastric mucosae and its possible association with gastric cancer risk. *Clin. Cancer Res.* **12**: 989–995.
- Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, Hines OJ, Reber H, Seligson DB, Horvath S, Kurdistani SK, Guha C, Dawson DW. 2010. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. *J. Clin. Oncol.* **28**: 1358–1365.
- Margueron R, Reinberg D. 2010. Chromatin structure and the inheritance of epigenetic information. *Nat. Rev. Genet.* **11**: 285–296.
- Maze I, Covington HE, 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovskiy A, Schaefer A, Nestler EJ. 2010. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. *Science* **327**: 213–216.
- McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, Turecki G, Meaney MJ. 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat. Neurosci* **12**: 342–348.
- Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature* **454**: 766–770.
- Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nat. Rev. Cancer* **6**: 38–51.
- Muller K, Heller H, Doerfler W. 2001. Foreign dna integration. genome-wide perturbations of methylation and transcription in the recipient genomes. *J. Biol. Chem.* **276**: 14271–14278.
- Nagao M, Ochiai M, Okochi E, Ushijima T, Sugimura T. 2001. LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences. *Mutat. Res.* **477**: 119–124.
- Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. 2009. The presence of a methylation fingerprint of *Helicobacter pylori* infection in human gastric mucosae. *Int. J. Cancer* **124**: 905–910.
- Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, Ichinose M, Sugimura T, Ushijima T, Saito D. 2006. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. *Cancer Epidemiol Biomarkers Prev.* **15**: 2317–2321.
- Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. 2008. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. *Hepatology* **47**: 908–918.
- Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T. 2010. Inflammatory processes triggered by *Helicobacter pylori* infection cause

- aberrant DNA methylation in gastric epithelial cells. *Cancer Res.* **70**: 1430–1440.
- Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, Ushijima T. 2009. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. *Cancer* **115**: 3412–3426.
- Okano M, Xie S, Li E. 1998. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat. Genet.* **19**: 219–220.
- Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell.* **99**: 247–257.
- Okochi-Takada E, Ichimura S, Kaneda A, Sugimura T, Ushijima T. 2004. Establishment of a detection system for demethylating agents using an endogenous promoter CpG island. *Mutat. Res.* **568**: 187–194.
- Oyer JA, Chu A, Brar S, Turker MS. 2009. Aberrant epigenetic silencing is triggered by a transient reduction in gene expression. *PLoS One* **4**: e4832.
- Ozsolak F, Song JS, Liu XS, Fisher DE. 2007. High-throughput mapping of the chromatin structure of human promoters. *Nat. Biotechnol.* **25**: 244–248.
- Park SY, Yoo EJ, Cho NY, Kim N, Kang GH. 2009. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for *Helicobacter pylori* infection. *J. Pathol.* **219**: 410–416.
- Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P. 2003. Psammplins from the sponge *Pseudoceratina purpurea*: inhibition of both histone deacetylase and DNA methyltransferase. *J. Org. Chem.* **68**: 3866–3873.
- Poirier LA. 2002. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. *J. Nutr.* **132**: 2336S–2339S.
- Pulling LC, Vuilleminot BR, Hutt JA, Devereux TR, Belinsky SA. 2004. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. *Cancer Res.* **64**: 3844–3848.
- Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. 2009. A human B cell methylome at 100-base pair resolution. *Proc. Natl. Acad. Sci. USA* **106**: 671–678.
- Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP. 2008. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. *Proc. Natl. Acad. Sci. USA* **105**: 252–257.
- Reichard JF, Schnekenburger M, Puga A. 2007. Long term low-dose arsenic exposure induces loss of DNA methylation. *Biochem Biophys Res. Commun* **352**: 188–192.
- Richards EJ, Elgin SC. 2002. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. *Cell.* **108**: 489–500.
- Riggs AD, Xiong Z. 2004. Methylation and epigenetic fidelity. *Proc. Natl. Acad. Sci. USA* **101**: 4–5.
- Robertson KD. 2005. DNA methylation and human disease. *Nat. Rev. Genet.* **6**: 597–610.
- Ruthenburg AJ, Li H, Patel DJ, Allis CD. 2007. Multivalent engagement of chromatin modifications by linked binding modules. *Nat. Rev. Mol. Cell. Biol.* **8**: 983–994.
- Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, Acuna C, Salazar AM, Lizano M, Duenas-Gonzalez A. 2003. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. *Clin. Cancer Res.* **9**: 1596–1603.
- Seligson DB, Horvath S, McBrien MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. 2009. Global levels of histone modifications predict prognosis in different cancers. *Am. J. Pathol* **174**: 1619–1628.
- Shi Y. 2007. Histone lysine demethylases: emerging roles in development, physiology and disease. *Nat. Rev. Genet* **8**: 829–833.
- Shivapurkar N, Wilson MJ, Poirier LA. 1984. Hypomethylation of DNA in ethionine-fed rats. *Carcinogenesis* **5**: 989–992.
- Snyder RD, Green JW. 2001. A review of the genotoxicity of marketed pharmaceuticals. *Mutat. Res.* **488**: 151–169.
- Stadtman ER, Barker HA. 1949. Fatty acid synthesis by enzyme preparations of *Clostridium kluyveri*; a consideration of postulated 4-carbon intermediates in butyrate synthesis. *J. Biol. Chem.* **181**: 221–235.
- Stewart MD, Li J, Wong J. 2005. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. *Mol. Cell. Biol.* **25**: 2525–2538.
- Takeshima H, Ushijima T. 2010. Methylation destiny: Moira takes account of histones and RNA polymerase II. *Epigenetics* **5**: 89–95.
- Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. 2009. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. *Genome Res.* **19**: 1974–1982.
- Takeshima H, Suetake I, Shimahara H, Ura K, Tate S, Tajima S. 2006. Distinct DNA methylation activity of Dnmt3a and Dnmt3b towards naked and nucleosomal DNA. *J. Biochem.* **139**: 503–515.
- Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. 1999. CpG island methylator phenotype in colorectal cancer. *Proc. Natl. Acad. Sci. USA* **96**: 8681–8686.
- Toyota M, Itoh F, Kikuchi T, Satoh A, Obata T, Suzuki H, Ishii S, Endo T, Tokino T, Imai K. 2002. DNA methylation changes in gastrointestinal disease. *J. Gastroenterol* **37** Suppl **14**: 97–101.
- Ushijima T. 2005. Detection and interpretation of altered methylation patterns in cancer cells. *Nat. Rev. Cancer* **5**: 223–231.
- Ushijima T. 2007. Epigenetic field for cancerization. *J. Biochem Mol. Biol.* **40**: 142–150.
- Ushijima T, Sasako M. 2004. Focus on gastric cancer. *Cancer Cell.* **5**: 121–125.
- Ushijima T, Okochi-Takada E. 2005. Aberrant methylations in cancer cells: Where do they come from? *Cancer Sci.* **96**: 206–211.
- Ushijima T, Asada K. 2010. Aberrant DNA methylation in contrast with mutations. *Cancer Sci.* **101**: 300–305.

- Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. 2003. Fidelity of the methylation pattern and its variation in the genome. *Genome Res.* **13**: 868–874.
- van Panhuys N, Le Gros G, McConnell MJ. 2008. Epigenetic regulation of Th2 cytokine expression in atopic diseases. *Tissue Antigens* **72**: 91–97.
- Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* **419**: 624–629.
- Villar-Garea A, Fraga MF, Espada J, Esteller M. 2003. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. *Cancer Res.* **63**: 4984–4989.
- Waki T, Tamura G, Sato M, Motoyama T. 2003. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. *Oncogene* **22**: 4128–4133.
- Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. 2008. Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat. Genet.* **40**: 897–903.
- Waterland RA, Jirtle RL. 2003. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol. Cell. Biol.* **23**: 5293–5300.
- Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. 2007. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. *Nat. Genet.* **39**: 457–466.
- Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyansky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. *Science* **318**: 1108–1113.
- Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenisch R. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. *Proc. Natl. Acad. Sci. USA* **102**: 13580–13585.
- Yamashita S, Hosoya K, Gyobu K, Takeshima H, Ushijima T. 2009. Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. *DNA Res.* **16**: 275–286.
- Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M. 2004. Identification of aberrantly methylated genes in association with adult T-cell leukemia. *Cancer Res.* **64**: 6002–6009.
- Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. *J. Biol. Chem.* **265**: 17174–17179.
- Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. 1997. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. *Proc. Natl. Acad. Sci. USA* **94**: 10907–10912.
- Zheng C, Hayes JJ. 2003. Structures and interactions of the core histone tail domains. *Biopolymers* **68**: 539–546.
- Zhou X, Li Q, Arita A, Sun H, Costa M. 2009. Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. *Toxicol. Appl. Pharmacol.* **236**: 78–84.

RESEARCH ARTICLE

Open Access

Two-step cleavage of hairpin RNA with 5' overhangs by human DICER

Yoshinari Ando¹, Yoshiko Maida², Ayako Morinaga¹, Alexander M Burroughs¹, Ryuichiro Kimura³, Joe Chiba³, Harukazu Suzuki¹, Kenkichi Masutomi^{2,4}, Yoshihide Hayashizaki^{1*}

Abstract

Background: DICER is an RNase III family endoribonuclease that processes precursor microRNAs (pre-miRNAs) and long double-stranded RNAs, generating microRNA (miRNA) duplexes and short interfering RNA duplexes with 20~23 nucleotides (nts) in length. The typical form of pre-miRNA processed by the Drosha protein is a hairpin RNA with 2-nt 3' overhangs. On the other hand, production of mature miRNA from an endogenous hairpin RNA with 5' overhangs has also been reported, although the mechanism for this process is unknown.

Results: In this study, we show that human recombinant DICER protein (rDICER) processes a hairpin RNA with 5' overhangs *in vitro* and generates an intermediate duplex with a 29 nt-5' strand and a 23 nt-3' strand, which was eventually cleaved into a canonical miRNA duplex via a two-step cleavage. The previously identified endogenous pre-miRNA with 5' overhangs, pre-mmu-mir-1982 RNA, is also determined to be a substrate of rDICER through the same two-step cleavage.

Conclusions: The two-step cleavage of a hairpin RNA with 5' overhangs shows that DICER releases double-stranded RNAs after the first cleavage and binds them again in the inverse direction for a second cleavage. These findings have implications for how DICER may be able to interact with or process differing precursor structures.

Background

DICER plays a key role in RNA interference pathways through the biogenesis of microRNA (miRNA) and small interfering RNA (siRNA) [1-3]. Most miRNA genes are transcribed as long primary transcripts (pri-miRNAs) where stem-loop structures with mature miRNA sequences embedded in the arm of a stem are cleaved by the Drosha nuclear microprocessor complex releasing a precursor miRNA (pre-miRNA) hairpin [4,5]. The cleavage site is determined mainly by the distance (~11 bp) from the stem-single stranded RNA junction of pri-miRNA and most pre-miRNAs have 2 nt-3' overhangs [6]. Pre-miRNAs, exported into the cytoplasm by Exportin-5 and Ran-GTP [7], are processed by the RISC loading complex (RLC) into 20~23 nt duplexes where the RNase III enzyme DICER plays a central role together with the double stranded (ds) RNA-binding proteins TRBP and PACT and the

miRNA-associated RNA-induced silencing complex (miRISC) core component Argonaute-2 (AGO2) [8-10]. miRNA duplexes processed by RLC are finally loaded to miRISC as a double stranded-structure [11] and separated into the functional guide strand, which is complementary to the target, and the passenger strand, which is subsequently degraded [12,13]. Strand selection of the functional guide strand by AGO2 depends on the thermodynamic stabilities of the base pairs at the 5' ends of the two strands [12,14,15]. Duplexes of siRNA or miRNA produced by DICER can be loaded in either direction to Argonaute [16-18]. Indeed, the mature miRNA either in the 5' or 3' strands can be harboured from pre-miRNA [19-21]. On the other hand, endogenous human AGO2 can bind directly to pre-miRNAs in DICER-knockout cells [22]. Recently, it was reported that human DICER is not essential for loading dsRNAs to AGO2 but functions in pre-selection of effective siRNAs for handoff to AGO2 [23].

Human DICER is a ~220 kDa protein consisting of several domains; an N-terminal DExH-box RNA helicase-like domain, a DUF283 domain, a PAZ domain,

* Correspondence: yoshihide@gsc.riken.jp

¹RIKEN Omics Science Center, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

Full list of author information is available at the end of the article

two RNase III domains (RIIIa and RIIIb), and a dsRNA binding motif domain (DARM) [24]. The two RNase III domains of DICER form a single dsRNA processing center via intramolecular dimerization which together cleave the opposite strands of the dsRNA, generating dinucleotide-long 3' overhangs on both ends [25]. The crystal structure of Dicer from *Giardia intestinalis* showed that the hydrophobic pocket of the PAZ domain was responsible for the binding of the 3' dinucleotide overhangs of the substrate and the connector helix between the PAZ domain and RNase III domain functioned as a molecular ruler measuring the distance from the 3' end of pre-miRNA to the cleavage site [26,27]. However, 3'-dinucleotide dsRNA overhangs are not essential for binding with DICER [28]. When the 3' overhang is removed, DICER can still cleave dsRNA through interaction with the remaining 5' overhang [28]. This is consistent with MacRae et al. who found that the recombinant Dicer protein of *Giardia intestinalis* could cleave the dsRNA with 5' overhangs [27]. However, they used perfectly matched dsRNAs with no gap, which might resemble an endogenous siRNA precursor. An additional study by Flores-Jasso et al. showed that human recombinant DICER protein could nick either strand of a mononucleotide-5' overhanged pre-miRNA with some strand preferences [29]. Despite this, the detailed step mechanism for pre-miRNA cleavage, especially for the pre-miRNA with 5' overhangs, is not yet elucidated.

An alternative nuclear pathway of pre-miRNA biogenesis was described where a short intron with a hairpin can be spliced and debranched into pre-miRNA hairpin mimics (mirtrons) [30-32]. This processing pathway uses intron splicing machinery instead of the Drosha endonuclease; miRNA precursors generated from intronic sequences (debranched mirtrons) are believed to be incorporated into the canonical miRNA pathway as a substrate of DICER. Interestingly, mouse pre-mir-1982 is a mirtron with an 11 nt tail at the 5' end [33], although most mammalian mirtrons are hairpin structures with single nucleotide overhangs at both ends [32-34]. Mature mouse miR-1982* miRNA emerges without 11 nt-5' overhangs from deep sequencing data of murine cells [33,35] while the elimination mechanism of this 11 nt-5' tail is still unknown.

In this paper, we investigated the detailed processing pattern of hairpin RNAs containing 5' overhangs by human recombinant DICER. We show here that human recombinant DICER is able to process hairpin RNA with 5' overhangs and two-step cleavage by DICER forms the mature miRNA duplex from the hairpin RNAs. Additionally, pre-mmu-mir-1982 RNA, which is a natural hairpin RNA with 5' overhangs, is also

processed by a two-step cleavage mediated by human recombinant DICER protein *in vitro*.

Results and Discussion

Processing of the pre-miRNA by recombinant DICER protein

We prepared purified recombinant DICER1 (rDICER) protein containing a FLAG-tag at the N-terminus (see Figures 1A and 1B). This rDICER does not contain known DICER-binding partners, AGO2 and TRBP (see Figure 1C). In order to confirm activity, we attempted to cleave pre-miRNA hairpin RNA using the rDICER. Forty-five pmol of pre-mir-21 RNA (see Figure 2A) was incubated with 2 pmol of the purified rDICER at the indicated times followed by purification. The reacted RNA substrates were subjected to Northern blotting using probe-1, corresponding to the antisense sequence of bases 2-22 of pre-mir-21 (see Figure 2A). A single band, 23 nucleotides in length, appeared after 20 min incubation and gradually increased. Thus, the purified rDICER possessed reasonable pre-miRNA processing activity to produce ~23 nt mature miRNA *in vitro* (see Figure 2B).

Processing of the hairpin RNA with 5' overhangs, RNA-I, by recombinant DICER protein

Using this rDICER, we performed a cleavage assay on a designed pre-miRNA mimic of hairpin RNA with trinucleotide-5' overhangs (RNA-I, see Figure 3A) to analyze whether DICER could process a hairpin RNA with 5' overhangs. The cleavage products were detected by Northern blotting using three different probes, probe-1, probe-2 and probe-3, corresponding to antisense





Figure 1 Characterization of recombinant DICER protein.

Purified rDICER (3 µg) was loaded onto a NuPAGE 4-12% Bis-Tris gel. Proteins were analyzed by Coomassie Brilliant Blue (CBB) staining (A) and Western blotting with anti-DICER antibody (B). (C) Western blotting with anti-DICER, anti-FLAG, anti-AGO2 and anti-TRBP antibodies. 30 µg of 293T cell lysate (lane 1) and 3 µg of rDICER (lane 2) were loaded.




sequences of bases 11-32, bases 49-69 and bases 33-48 of RNA-I, respectively (see Figure 3A). Using probe-1, band 1 (~30nt) appeared after 20 min incubation and gradually increased through a 50 min-incubation. This processing pattern was similar to that of the around 23-nt product generated from native pre-miRNA by rDICER (see Figures 2B and 3B). After 40 min incubation, band 2 (~23nt) was detected and the abundance of band 2 increased in a time-dependent manner (see Figure 3B). Additionally, using probe-2, band 3 (~23nt) was detected from the 30-min incubation sample (see Figure 3C). Using probe-3, band 4 (~22nt) was detected from the 20-min incubation sample (see Figure 3D). The processing activity on the hairpin RNA with 5' overhangs is comparable to that for natural pre-miRNA. This means that hairpin RNA with 5' overhangs could also be a substrate for rDICER processing.

To analyze band 1 at a longer incubation time, the RNA-I was incubated with the purified rDICER and the cleavage reactions were performed for 30 min and 16 hours. Surprisingly, band 1 was detected at 30 min incubation but disappeared after 16-hours incubation. On the other hand, band 2 continued to accumulate (see Figure 3E). These results showed that band 1, which seems to be a product of first processing by rDICER, disappeared following an extended incubation time.

Next, to verify the size of the cleavage products of RNA-I, we cloned the 23-nt products after 16-hour rDICER incubation and sequenced them (see Table 1). Several clones were obtained from 5'-strand, 3' strand and loop region of RNA-I corresponding to bands 2-4 in Figure 3, respectively. The miRNA length heterogeneity generated by rDICER is consistent with the finding in the previous report [36]. Clones from the 5' strand lacking 6 or 7 nt the initial of the 5' end of RNA-I and clones from 3' strand lack the terminal 1 or 2 nt of the 3' end of RNA-I.

To analyze how band 1 is further processed, we labelled the 5' end of the RNA-I and incubated the samples with rDICER (see Figure 4A). Time course experiments and cloning results indicated that rDICER could process the 5'-labelled RNA-I at the 29-nt position from its 5' end (band 1) after 20 min incubation and subsequently cleave the 29-nt short RNA at the 6-nt position from its 5' end to 23-nt RNA (band 2) after 40 min incubation (see Figure 4A, 4B, and Table 1). This suggests dsRNAs with a 29 nt-5' strand and a 23 nt-3' strand are processed by rDICER from RNA-I at the first cleavage and released once from the enzyme. After this, rDICER binds the dsRNA again and, measuring from the 3' end of the 29-nt strand, generates 23-22 nt RNA duplexes via a second cleavage reaction (see Figure 5).

In this research, we found that hairpin RNA with trinucleotide-5' overhangs was cleaved into a 23-22 nt RNA duplex through two-step processing by rDICER. This could not be detected if we used only end-labelled RNA or label-incorporated RNA as a substrate for rDICER as reported previously [27,29]. In the first step, rDICER processes the hairpin RNA with 5' overhangs to dsRNA with 29 nt and 23 nt. Our results indicate the first processed dsRNA binds again in the inverse direction with the same or a different rDICER molecule and is again effectively cleaved. The results are consistent with the previous report that human DICER protein binds either 3' ends of dsRNA strand on the PAZ domain and cleaves dsRNA at the ~23 nt position from the binding end [25]. In the sequential process described here, dsRNAs with 29 nt and 23 nt gradually increased and then stabilized at a steady level, followed by rapid increase of 23-22 nt duplexes (see Figure 3B and 3C). This indicates that dsRNAs with 29 nt and 23 nt are






Figure 5 Model of the two-step processing of hairpin RNA with 5' overhangs (RNA-I) by DICER protein. rDICER processes hairpin RNA with 5' overhangs (RNA-I) to dsRNA with 29 nt-5' strand and 23 nt-3' strand after the first cleavage reaction and releases once from the binding site. Then, the dsRNA is bound in the inverse direction with the same or different rDICER molecule and is measured after the anchoring 3' end of the 29-nt strand to generate dsRNA with 23 nt cleaved from the 29-nt strand and 22 nt cleaved from the 23-nt strand. "PAZ" domain of rDICER colored purple; "RIIIa" and "RIIIb" domain of rDICER colored blue. Lightning marks indicate the cleavage sites in the RNA.




Figure 6 Processing of pre-mmu-mir-1982 RNA by recombinant DICER protein. (A) Pre-mmu-mir-1982 RNA and probes used in this study. The secondary structure was predicted using the CentroidFold program [49]. The solid line shows the position of probe-4 and the dashed line shows the position of probe-5. (B-C) Time-course analysis of the processing of pre-mmu-mir-1982 RNA by the rDICER protein. pre-mmu-mir-1982 RNAs were incubated with rDICER *in vitro* for the indicated time points (0, 10, 20, 30, 40, 50, 60, 75, 90, 105 and 120 min). The RNAs processed by rDICER were detected using probe-4 (B), probe-5 (C) by Northern blotting. The gray arrow shows the band of unprocessed RNA and the black arrow shows the bands of small RNA processed from the 5' strand and 3' strand of pre-mmu-mir-1982 RNA respectively. M: decade marker.




Figure 7 Two-step processing of the 5'-end labelled pre-mmu-mir-1982 RNA by recombinant DICER protein. (A) *In vitro* processing of the pre-mmu-mir-1982 RNA by the rDICER protein at a longer incubation time. 5' labelled pre-mmu-mir-1982 RNAs were incubated with rDICER for 0, 2 and 16 hours. The gray arrow shows the band of unprocessed RNA and the black arrow shows the bands of small RNA processed from pre-mmu-mir-1982 RNA. AH: the alkaline hydrolysis ladder of pre-mmu-mir-1982 RNA. The size of each band was determined by the AH ladder. **(B-C)** The signal intensities were quantified from the 12 nt **(B)** and 35 nt **(C)** bands in Figure 7A. These plots show average values bracketed by s.e.m. error bars; calculated from two independent experiments. Background refers to the signal intensity of the same sized band in the AH lane. The p-value was calculated using a simple t-test for each time point (2 hrs and 16 hrs) relative to the background. Significant differences ($p < 0.05$) in signal intensities are denoted with an asterisk. The significant calculated p-values are as follows: the 12-nt band at 16 hours, $p = 0.017$; the 35-nt band at 2 hours, $p = 0.0073$; and the 35-nt band at 16 hours, $p = 0.024$.

Conclusions

We show human rDICER recognizes and processes a hairpin RNA bearing a trinucleotide-5' overhang, and the two-step cleavage by rDICER forms canonical miRNA duplexes from the hairpin RNAs. It indicates that human rDICER functions as a molecular ruler by anchoring the 3' end of both the hairpin RNA with 5' overhangs and the 5' strand in the intermediate duplex. Moreover, an endogenously-expressed pre-miRNA with 5' overhangs, pre-mmu-mir-1982, also can be utilized as a substrate of rDICER and processed into a canonical miRNA duplex by the two-step cleavage reaction. While pre-mmu-mir-1982 RNA is a naturally expressed pre-miRNA [33,35], this 5'-overhanged structure is not a suitable substrate for nuclear export by Exportin-5 [43] and, assuming the absence of possible alternative export pathways, may not be presented to cytoplasmic DICER in the cells. However, it is worth noting a recent report, that mammalian DICER might be located in the nucleus and associate with ribosomal DNA chromatin [44]. We have also observed human DICER localized in both cytoplasm and nucleus (unpublished data, Ando et al.). These findings raise the intriguing possibility that nuclear DICER could process hairpin RNA with 5'-overhangs, like pre-mmu-mir-1982 RNA.

The two-step cleavage of a hairpin RNA with 5' overhangs shows that rDICER can release dsRNAs after the first cleavage and binds them again in the inverse direction for a second cleavage. The DICER protein's ability to release and bind dsRNA again indicates DICER could be capable of binding and processing dsRNA multiple times during short RNA maturation. DICER has recently been linked to the processing of diverse non-coding RNA precursors with as-yet undetermined structures. The experiments performed above suggest DICER has considerable flexibility in processing precursors, contributing to an ability to generate various short RNA products for incorporation into functional RISCs.

Methods

Preparation of hairpin RNA substrates

Pre-hsa-mir-21 RNA (pre-mir-21), pre-miRNA mimic hairpin RNA (RNA-I) and pre-mmu-mir-1982 RNA used in this study were generated by *in vitro* transcription using the Ampliscribe T7 High Yield Transcription kits (Epicentre) according to manufacturer's instructions. We made double-stranded DNA templates with T7 RNA polymerase promoter sequence by overlap-PCR using the following oligonucleotide pair; pre-mir-21-sense 5'-taactgactactatagAGCTTATCAGACTGATGTTGACTG-3' and pre-mir-21-antisense 5'-ACAGCC-CATCGACTGGTGTGCCATGAGATTCAACAGT-CAACATC-3', RNAI-sense 5'-taactgactactataggg

TGTCGGGTAGCTTATCAGACTGATGTGTA-3' and RNAI-antisense 5'-TGTCAGACAGCCCATCGACTG GTGTTGCCATGAGATTCAACAGTCAACA-3', pre-mmu-mir-1982-sense 5'-taactgactactataGTTGG-TATTGCTTGGGAGGGTCTTGGGGAGGGAGTT-3' and pre-mmu-mir-1982-antisense 5'-CTGTGGGAGAA-CATAGGGTGAGAGGGTTGGGGTGCCAGAACTCCCTCCCCA-3'. The overlapped sequences are underlined and the lower-case characters show the sequence of the T7 RNA polymerase promoter. *In vitro* transcription reactions were performed at 37°C overnight. Transcripts were run on 10% denaturing polyacrylamide gels in 0.5x TBE (45 mM Tris-borate, 1 mM EDTA), gel-excised, eluted from the gel in 1 M NaCl at 4°C overnight, and precipitated with ethanol. The pellet was resuspended in an appropriate volume of water and stored into the freezer at -30°C. Before use, RNA substrates were heated to 70°C for 5 min and then slowly cooled to room temperature.

Affinity purification of recombinant FLAG-DICER1 fusion proteins

We assembled a full-length cDNA of human DICER1 protein from HeLa total RNA. This cDNA sequence was identical to the coding sequence cited in the Swiss-Prot Protein Database (Swiss-Prot) [Swiss-Prot: Q9UPY3]. N-terminally FLAG-tagged human DICER1 protein was purified from 293T cells transfected with the plasmid pCA-FLAG-DICER1. This vector contained the full-length human DICER1 protein FLAG-tagged at the amino terminus in a pCA-FLAG-DEST vector [45]. We purified the recombinant FLAG-DICER1 fusion protein (rDICER) using ANTI-FLAG M2-Agarose Affinity Gel (Sigma) and eluted by 0.1 M Glycine-HCl (pH3.5). Then, the eluate was neutralized by Tris-HCl (pH8.0). The average yield was 50-100 µg of the active form of rDICER protein from 1 × 10⁸ culture cell. Purified rDICER protein was detected by Coomassie Brilliant Blue (CBB) staining and Western blotting using anti-DICER (H212, Santa Cruz) antibody to check for successful homogenous purification (see Figures 1A and 1B). The contamination of known DICER-binding proteins in rDICER samples was checked by Western blotting using anti-FLAG (M2, Sigma), anti-AGO2 (07-590, Upstate) and anti-TRBP (ab42018, Abcam) antibody, respectively (see Figure 1C).

Processing of RNA substrates using recombinant DICER1 enzyme

The affinity-purified rDICER protein (2 pmol) was incubated with 45 pmol of RNA substrates (pre-mir-21 RNA, RNA-I or pre-mmu-mir-1982 RNA) in 1x reaction buffer (300 mM NaCl, 50 mM Tris-HCl, 20 mM

HEPES, 5 mM MgCl₂, pH 9.0) and 40 units of RNase-OUT (Invitrogen). These mixtures were incubated at 37°C for the indicated times. The reactions were purified by phenol-chloroform extraction followed by sodium acetate-ethanol precipitation at -20°C. The RNA pellet was resuspended in water at a final concentration of approximately 1 pmol/μl.

Northern blotting

rDICER-processed RNAs (1 pmol) were separated on 7 M urea-denaturing 20% polyacrylamide gels, then blotted onto Hybond-N+ membranes (GE Healthcare) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Hybridization was performed in Church buffer (0.5 M NaHPO₄, pH 7.2, 1 mM EDTA and 7% SDS) containing 10⁶ c.p.m./ml of each ³²P-labelled probe for 14 h. The membranes were washed in 2x SSC, and the signals were detected by autoradiography. All experiments were repeated and replicated consistently.

The probe sequences in this study were as follows: probe-1 (5'-TCAACATCAGTCTGATAAGCTA-3'), probe-2 (5'-ACAGCCCATCGACTGGTGTG-3'), probe-3 (5'-CCATGAGATTCACAG-3'), probe-4 (5'-CTCTCCCAGGACCTCCAA-3') and probe-5 (5'-CTGTGGGAGAACATAGGGTGA-3'). The probes were 5'-end labelled using T4 polynucleotide kinase (TaKaRa Bio) with [³²P] ATP (6000Ci/mmol) at 37°C for 4 h.

Cloning of cleavage products

rDICER-processed RNAs (1 pmol) were separated on 7 M urea-denaturing 15% polyacrylamide gels, then the gel was stained by SYBR Gold (Invitrogen). The band around 23 nt was excised from the gel and purified as described above. The purified RNA was cloned by the Small RNA cloning kit (TaKaRa Bio) and sequenced by capillary sequencing.

5'-end labelling of the transcript

For the 5'-end labelling, RNA (45 pmol) was dephosphorylated with CIP at 37°C for 60 min. The reaction was inactivated by phenol-chloroform extraction and precipitated by sodium acetate-ethanol at -20°C. The pellet was resuspended in an appropriate volume of water. The dephosphorylated transcript was 5' end-labelled using T4 polynucleotide kinase (TaKaRa Bio) with [³²P] ATP (3000Ci/mmol) at 37°C for 4 h. The 5'-end labeled transcript was PAGE-purified as described above and the RNA pellet was resuspended in water at a final concentration of approximately 0.5 pmol/μl. One microliter of this was used for the processing reaction by rDICER. These processed samples were run on 7.5 M urea-denaturing 20% polyacrylamide gels in 1x TBE buffer with RNA molecular

marker or the products of alkaline hydrolysis of the same RNA molecule. The alkaline hydrolysis ladder was generated by incubating the labelled RNA in alkaline hydrolysis buffer (Ambion) at 100°C for 10 min. The signals were detected by autoradiography and quantified using ImageJ software (National Institutes of Health; <http://rsb.info.nih.gov/ij/>). The signal intensities were calculated as the mean of pixel value of selected area.

Additional material

Additional file 1: Supplementary information.

Acknowledgements

We thank Drs. Yasuhiro Tomaru, Timo Lassmann and Masanori Suzuki for their helpful discussion. We also thank Dr. Junichi Yano (Nippon Shinyaku Co. Ltd., Kyoto) for the gift of materials. We acknowledge to RIKEN GenAS for their support of our sequencing data production. This work was supported by a Research Grant for the RIKEN Omics Science Center from the Ministry of Education, Culture, Sports, Science and Technology of Japan to YH.

Author details

¹RIKEN Omics Science Center, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan. ²Cancer Stem Cell Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ³Department of Biological Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. ⁴PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan.

Authors' contributions

YA conceived the study, designed and performed experiments and drafted the manuscript. YM and AM participated in the experimental design and performed experiments. RK and JC participated in the experimental design and purified recombinant FLAG-DICER fusion proteins. AMB, HS and KM participated in the design of the study and revised the manuscript. YH designed the research project, provided funding, supervised the study and critically reviewed the manuscript. All authors read and approved the final manuscript.

Received: 21 June 2010 Accepted: 9 February 2011

Published: 9 February 2011

References

1. Sontheimer EJ: Assembly and function of RNA silencing complexes. *Nat Rev Mol Cell Biol* 2005, 6(2):127-138.
2. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol* 2009, 10(2):126-139.
3. Jinek M, Doudna JA: A three-dimensional view of the molecular machinery of RNA interference. *Nature* 2009, 457(7228):405-412.
4. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: Processing of primary microRNAs by the Microprocessor complex. *Nature* 2004, 432(7014):231-235.
5. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. *Nature* 2004, 432(7014):235-240.
6. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT, Kim VN: Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. *Cell* 2006, 125(5):887-901.
7. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. *Science* 2004, 303(5654):95-98.
8. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R: Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell* 2005, 123(4):631-640.

9. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN: The role of PACT in the RNA silencing pathway. *EMBO J* 2006, **25**(25):5225-5232.
10. Macrae IJ, Ma E, Zhou M, Robinson CV, Doudna JA: In vitro reconstruction of the human RISC-loading complex. *Proc Natl Acad Sci USA* 2008, **105**(2):512-517.
11. Tahbaz N, Kolb FA, Zhang H, Jaranczyk K, Filipowicz W, Hobman TC: Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer. *EMBO Rep* 2004, **5**(2):189-194.
12. Schwarz DS, Hutvagner G, Du T, Xu Z, Avolin N, Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. *Cell* 2003, **115**(2):199-208.
13. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat Cell Biol* 2009, **11**(3):228-234.
14. Khorovova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. *Cell* 2003, **115**(2):209-216.
15. Yoda M, Kawamata T, Paroo Z, Ye X, Iwasaki S, Liu Q, Tomari Y: ATP-dependent human RISC assembly pathways. *Nat Struct Mol Biol* 2010, **17**(1):17-23.
16. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD: A protein sensor for siRNA asymmetry. *Science* 2004, **306**(5700):1377-1380.
17. Tomari Y, Du T, Zamore PD: Sorting of Drosophila small silencing RNAs. *Cell* 2007, **130**(2):299-308.
18. Wang HW, Noland C, Siddehadiolk R, Taylor DM, Ma E, Felderer K, Doudna JA, Nogales E: Structural insights into RNA processing by the human RISC-loading complex. *Nat Struct Mol Biol* 2009, **16**(11):1148-1153.
19. Tomari Y, Zamore PD: Perspective: machines for RNAi. *Genes Dev* 2005, **19**(5):517-529.
20. Hu HY, Yan Z, Xu Y, Hu H, Menzel C, Zhou YH, Chen W, Khaitovich P: Sequence features associated with microRNA strand selection in humans and flies. *BMC Genomics* 2009, **10**:413.
21. Furukoshi AM, Ando Y, de Hoon MJ, Tomaru Y, Nishibu T, Uekitawa R, Funakoshi T, Kurokawa T, Suzuki H, Hayashizaki Y, et al: A comprehensive survey of 3' animal miRNA modification events and a possible role for 3' adenylation in modulating miRNA targeting effectiveness. *Genome Res* 2010, **20**(10):1398-1410.
22. Tan GS, Gorchow BG, Liu X, Yeung J, Morris JPt, Cueller TL, McManus MT, Kiriakidou M: Expanded RNA-binding activities of mammalian Argonaute 2. *Nucleic Acids Res* 2009, **37**(2):7533-7545.
23. Sakurai K, Amarguiouli M, Kim DH, Alluin J, Heale B, Song MS, Gatignol A, Behlke MA, Rossi JJ: A role for human Dicer in pre-RISC loading of siRNAs. *Nucleic Acids Res* 2010.
24. Macrae IJ, Doudna JA: Ribonuclease revisited: structural insights into ribonuclease III family enzymes. *Curr Opin Struct Biol* 2007, **17**(1):138-145.
25. Zhang H, Kolb FA, Jasiewicz Z, Westhof E, Filipowicz W: Single processing center models for human Dicer and bacterial RNase III. *Cell* 2004, **118**(1):57-68.
26. Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, Adams PD, Doudna JA: Structural basis for double-stranded RNA processing by Dicer. *Science* 2006, **311**(5758):195-198.
27. Macrae IJ, Zhou K, Doudna JA: Structural determinants of RNA recognition and cleavage by Dicer. *Nat Struct Mol Biol* 2007, **14**(10):934-940.
28. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W: Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. *EMBO J* 2002, **21**(21):5875-5885.
29. Flores-Jasso CF, Arenas-Huertero C, Reyes JL, Contreras-Cubas C, Covarrubias A, Vaca L: First step in pre-miRNAs processing by human Dicer. *Acta Pharmacol Sin* 2009, **30**(8):1177-1185.
30. Ruby JG, Jan CH, Bartel DP: Intronic microRNA precursors that bypass Drosha processing. *Nature* 2007, **448**(7149):83-86.
31. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC: The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. *Cell* 2007, **130**(1):89-100.
32. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC: Mammalian mirtron genes. *Mol Cell* 2007, **28**(2):328-336.
33. Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R: Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. *Genes Dev* 2008, **22**(20):2773-2785.
34. Glazov EA, Kongsuwan K, Assavapitskul W, Horwood PF, Mitter N, Wathony T: Repertoire of bovine miRNA and miRNA-like small regulatory RNAs expressed upon viral infection. *PLoS One* 2009, **4**(7):e6349.
35. Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spier N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al: Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. *Genes Dev* 2010, **24**(10):992-1009.
36. Starega-Roslan J, Krol J, Koscianska E, Kozlowski P, Szlachetnik J, Sobczak K, Krzyzosiak WJ: Structural basis of microRNA length variety. *Nucleic Acids Res* 2011, **39**(1):257-268.
37. Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, Cheloufi S, Hodges E, Anger M, Sachidanandan R, Schultz RM, et al: Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. *Nature* 2008, **453**(7194):534-538.
38. Watanabe T, Totoki Y, Toyoda A, Kaneda M, Kuramochi-Miyagawa S, Obata Y, Chiba H, Kohara Y, Kono T, Nakano T, et al: Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. *Nature* 2008, **453**(7194):539-543.
39. Maida Y, Yasukawa M, Furuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K: An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* 2009, **461**(7261):230-235.
40. Burroughs AM, Ando Y, Hoon MJ, Tomaru Y, Suzuki H, Hayashizaki Y, Doudna CO: Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. *RNA Biol* 2011.
41. Azuma-Mukai A, Oguri H, Miyajima T, Olan ZR, Asai K, Siomi H, Siomi MC: Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing. *Proc Natl Acad Sci USA* 2008, **105**(23):7964-7969.
42. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschli T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. *EMBO J* 2001, **20**(23):6877-6888.
43. Okada C, Yamashita E, Lee SJ, Shibata S, Katsuhira J, Nakagawa A, Yoneda Y, Tsukahara T: A high-resolution structure of the pre-miRISC associated export machinery. *Science* 2009, **326**(5957):1275-1279.
44. Sinkkonen L, Huggenschmidt T, Filipowicz W, Svoboda P: Dicer is associated with ribosomal DNA chromatin in mammalian cells. *PLoS One* 2010, **5**(8):e12175.
45. Kimura R, Yoda A, Hayashizaki Y, Chiba J: Novel ELISA using intracellularly biotinylated antigen for detection of antibody following DNA immunization. *Jpn J Infect Dis* 2010, **63**(1):41-48.
46. Griffiths-Jones S: The microRNA Registry. *Nucleic Acids Res* 2004, **32** Database: D109-111.
47. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res* 2006, **34** Database: D140-144.
48. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. *Nucleic Acids Res* 2008, **36** Database: D154-158.
49. Sato K, Hamada M, Asai K, Mityama T: CENTROIDFOLD: a web server for RNA secondary structure prediction. *Nucleic Acids Res* 2009, **37** Web Server: W277-280.

doi:10.1186/1471-2199-12-6

Cite this article as: Ando et al.: Two-step cleavage of hairpin RNA with 5' overhangs by human DICER. *BMC Molecular Biology* 2011 **12**:6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



A histopathological study for evaluation of therapeutic effects of radiofrequency ablation in patients with breast cancer

Hitoshi Tsuda · Kunihiro Seki · Takahiro Hasebe ·
Yuko Sasajima · Tatsuhiro Shibata ·
Eriko Iwamoto · Takayuki Kinoshita

Received: 20 July 2010 / Accepted: 24 August 2010 / Published online: 23 September 2010
© The Japanese Breast Cancer Society 2010

Abstract

Purpose To reveal the rate of complete therapeutic effect of radiofrequency ablation (RFA) and its correlation with tumor size by the histopathological examination of surgically resected early breast cancers.

Methods For 28 patients who received RFA and subsequent surgical therapies for early breast cancer treatment, the effect of RFA was evaluated by both histopathological examination and nicotinamide adenine dinucleotide (NADH)-diaphorase staining of resected tumor specimens according to the criteria described by Seki et al. (this issue). The correlation of 100% RFA effect with tumor parameters including tumor size and the presence of extensive intraductal component (EIC) was examined.

Results The mean size and invasive size of the primary tumors were 2.21 cm (ranging from 0.6 to 5.0 cm) and 1.44 cm (ranging from 0 to 5.0 cm), respectively. By examining hematoxylin-eosin (HE) sections, the effectiveness of RFA was found to be 100% in 16 tumors (57%). However, the effectiveness of RFA was found to be 100% in 22 cases (79%) examined by NADH-diaphorase staining of frozen sections containing part of tumorous and nontumorous tissues. The accuracy of diagnosis of complete RFA effect using NADH-diaphorase staining with reference to HE was 79% (22 of 28) with 100% (16 of 16) sensitivity and 50% (6 of 12) specificity. The rate of 100% RFA effect by HE examination was higher in EIC(–) tumors (13 of 17, 76%) than in EIC(+) tumors (1 of 9, 11%) ($P = 0.0022$), and was higher in tumors of ≤ 1.5 cm (10 of 11, 91%) than in tumors of >1.5 cm (6 of 17, 35%; $P = 0.0034$). All five tumors of ≤ 1.0 cm showed 100% RFA effect, but 3 (27%) of 11 tumors of >1.0 and ≤ 2.0 cm and 9 (75%) of 12 tumors of >2.0 cm showed suboptimal RFA effect by HE.

Conclusions Tumor size of ≤ 1.5 cm, strictly ≤ 1.0 cm, could be an indication for RFA if a complete histological therapeutic effect is mandatory.

H. Tsuda (✉) · T. Hasebe · Y. Sasajima · T. Shibata
Pathology and Clinical Laboratory Division, National Cancer
Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
e-mail: hsttsuda@ncc.go.jp

K. Seki
Clinical Laboratory Division, JR Tokyo General Hospital,
2-1-3 Yoyogi, Shibuya-ku, Tokyo 151-8528, Japan

T. Hasebe
Pathology Consultation Service, Clinical Trials and Practice
Support Division, Center for Cancer Control and Information
Services, National Cancer Center, 5-1-1 Tsukiji,
Chuo-ku, Tokyo 104-0045, Japan

T. Shibata
Cancer Genomics Project, Center for Medical Genomics,
National Cancer Center Research Institute, 5-1-1 Tsukiji,
Chuo-ku, Tokyo 104-0045, Japan

E. Iwamoto · T. Kinoshita
Surgical Oncology Division, National Cancer Center Hospital,
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Keywords Radiofrequency ablation · Breast cancer ·
Therapeutic effect · NADH diaphorase

Introduction

Histopathological evaluation of radiotherapeutic effects in patients' cancerous tissues, including esophageal or cervical cancers, was established in Japan in the 1960s [1]. This system evaluates the percentage of area with markedly altered, presumably nonviable cancer cells, and the area

Table 1 Pathological findings and therapeutic effects in 28 tumors subjected to radiofrequency ablation (RFA)

No./age	Permanent section							Frozen section						
	Histology	Grade	pN	ER	PR	HER2	Tumor size (cm)	Invasive size (cm)	Daughter nodule	EIC	Area with RFA effect (cm)	RFA effect (HE) (%)	Tumor size in sample	NADH effect (%)
1/52/L	muc	1	0	2	0	1	2.4	2.4	–	–	6.6	100	1.6	100
2/69/R	Pred DCIS	1	0	3	1	1	2.2	0.08	–	NA	3.2	100	0.8	100
3/79/R	IDC(pap)	2	0	3	3	0	2.1	2.1	–	–	6	100	1.2	100
4/67/L	IDC(sol)	3	0	0	0	0	2	1.7	–	–	4.2	100	1.7	100
5/64/R	IDC(sol)	3	0	0	0	1	1.7	1	–	–	5.5	100	1.3	100
6/68/L	IDC(sec)	3	0	0	0	1	1.6	1.6	–	–	3.5	100	1.3	100
7/54/L	IDC(pap)	1	0	3	1	1	1.5	0.8	–	+	5.8	100	0.3	100
8/62/L	IDC(sol)	2	0	3	3	0	1.5	1.5	+	–	2.7	100	1.3	100
9/53/R	IDC(sec)	2	0	3	3	0	1.3	1.3	–	–	2.8	100	1.1	100
10/56/R	IDC(pap)	1	0	2	0	0	1.2	1.2	–	–	3.4	100	0.9	100
11/82/R	IDC(sec)	1	0	2	3	1	1.1	1.6	–	–	4	100	1	100
12/47/L	IDC(pap)	1	0	3	3	1	1	0.7	–	–	1.9	100	1	100
13/66/R	DCIS	NA	0	0	0	1	0.9	0	–	NA	4	100	0.8	100
14/67/L	IDC(sec)	2	1	3	2	1	0.8	0.8	–	–	3.7	100	0.9	100
15/42/R	IDC(pap)	1	1	2	2	0	0.6	0.5	–	–	3	100	0.7	100
16/38/L	IDC(pap)	1	0	1	0	1	0.5	0.2	–	–	2.4	100	0.5	100
17/52/R	IDC(sec)	1	3	3	3	0	5	5	–	–	5	90–95	2	90–95
18/45/L	IDC(pap)	1	3	1	3	1	4.7	1.1	+	+	3.9	30	0.5	100
19/57/L	IDC(sol)	1	0	3	2	0	4.7	2.1	–	+	1.7	40	0.7	90
20/78/R	IDC(pap)	1	1	3	0	0	4.2	1.2	–	+	4.7	95	1.2	100
21/48/R	IDC(sec)	2	0	1	3	0	4	2.4	–	+	4	60	1.3	90
22/59/L	IDC(sol)	3	0	0	0	3	3.5	2.6	–	+	3.9	40–50	1.5	40–50
23/62/R	IDC(pap)	1	0	3	3	1	3.2	1.1	–	+	2.6	60–70	1.6	80
24/73/L	IDC(sec)	1	0	3	1	1	2.5	2.5	–	–	3.3	90	1.4	100
25/60/L	IDC(sol)	1	0	3	3	0	2.5	1	–	+	2.5	95	1	100
26/43/L	IDC(sec)	1	0	3	3	1	2	0.8	–	–	2.5	95	0.4	100
27/63/L	IDC(pap)	1	0	3	3	1	1.8	1.5	–	+	1.7	80	1.5	0
28/69/L	muc	1	0	3	0	0	1.5	1.5	–	–	5.5	95	1.3	100

Tumor size includes both invasive and intraductal components

DCIS ductal carcinoma in situ, EIC extensive intraductal component, ER estrogen receptor, HE hematoxylin-eosin, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, L, left, muc mucinous carcinoma, MA not applicable, NADH nicotinamide adenine dinucleotide-diaphorase, pap papillotubular carcinoma, PR progesterone receptor, Pred DCIS predominantly DCIS, R right, scr scirrhous carcinoma, sol solid-tubular carcinoma